aspartic acid has been researched along with Adenocarcinoma in 43 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 9.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 5.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| " The extent of control of the EMT-6 mammary adenocarcinoma was determined using fractionated radiation (12 irradiations) over a 3-week period using the radiosensitizer 5-chloro-2'-deoxycytidine (CldC) and biomodulators of its metabolism: N-(Phosphonacetyl)-L-aspartate (PALA), tetrahydrouridine and 5-fluoro-2'-deoxycytidine (FdC)." | 3.69 | Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. ( Greer, S; Marion, HS; Schwade, J, 1995) |
| "To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma." | 3.69 | Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0." | 1.29 | Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993) |
| "Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers." | 1.26 | Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978) |
| "It was found that SV40-induced hamster tumors, BHK21/cl 13 cells in culture, certain carcinogen-induced tumors in the Ehrlich ascites tumor, and a number of human carcinomas and adenocarcinomas contained a distinct increase (3- to 20-fold) in the percentage of a late-eluting aspartyl-tRNA over that found in nonmalignant tissues, other animal tumors, and in human melanomas and sarcomas." | 1.25 | The distribution and properties of aspartyl transfer RNA in human and animal tumors. ( Bowen, JM; Briscoe, WT; Griffin, AC; McBride, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (23.26) | 18.7374 |
| 1990's | 21 (48.84) | 18.2507 |
| 2000's | 6 (13.95) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vorlova, B | 1 |
| Knedlik, T | 1 |
| Tykvart, J | 1 |
| Konvalinka, J | 1 |
| Zhou, Y | 1 |
| Lu, LN | 1 |
| Xin, X | 1 |
| Huo, DF | 1 |
| Wu, HB | 1 |
| Qiu, MF | 1 |
| Yamamoto, H | 1 |
| Higasa, K | 1 |
| Sakaguchi, M | 1 |
| Shien, K | 1 |
| Soh, J | 1 |
| Ichimura, K | 1 |
| Furukawa, M | 1 |
| Hashida, S | 1 |
| Tsukuda, K | 1 |
| Takigawa, N | 1 |
| Matsuo, K | 1 |
| Kiura, K | 1 |
| Miyoshi, S | 1 |
| Matsuda, F | 1 |
| Toyooka, S | 1 |
| Degrassi, A | 1 |
| Russo, M | 1 |
| Nanni, C | 1 |
| Patton, V | 1 |
| Alzani, R | 1 |
| Giusti, AM | 1 |
| Fanti, S | 1 |
| Ciomei, M | 1 |
| Pesenti, E | 1 |
| Texido, G | 1 |
| Liu, X | 1 |
| Germin, BI | 1 |
| Zhong, J | 1 |
| Ekholm, S | 1 |
| Rachagani, S | 1 |
| Senapati, S | 1 |
| Chakraborty, S | 1 |
| Ponnusamy, MP | 1 |
| Kumar, S | 1 |
| Smith, LM | 1 |
| Jain, M | 1 |
| Batra, SK | 1 |
| Pettersson, F | 1 |
| Dalgleish, AG | 1 |
| Bissonnette, RP | 1 |
| Colston, KW | 1 |
| Xing, DY | 1 |
| Qi, J | 1 |
| Tan, W | 1 |
| Miao, XP | 1 |
| Liang, G | 1 |
| Yu, CY | 1 |
| Lu, WF | 1 |
| Zhou, CN | 1 |
| Wu, M | 1 |
| Lin, DX | 1 |
| Johnston, PG | 1 |
| Benson, AB | 1 |
| Catalano, P | 1 |
| Rao, MS | 1 |
| O'Dwyer, PJ | 5 |
| Allegra, CJ | 2 |
| Whitehead, RP | 1 |
| Benedetti, JK | 1 |
| Abbruzzese, JL | 2 |
| Ardalan, B | 3 |
| Goodwin, JW | 1 |
| Balcerzak, SP | 1 |
| Samlowski, WE | 1 |
| Lenz, HJ | 1 |
| Macdonald, JS | 3 |
| Jiao, L | 1 |
| Hassan, MM | 1 |
| Bondy, ML | 1 |
| Evans, DB | 1 |
| Li, D | 1 |
| Rubin, J | 1 |
| Schutt, AJ | 1 |
| O'Connell, MJ | 1 |
| Gertz, MA | 1 |
| Moertel, CG | 1 |
| Earhart, RH | 1 |
| Elson, PJ | 1 |
| Rosenthal, SN | 1 |
| Hahn, RG | 1 |
| Slayton, RE | 1 |
| Natale, RB | 1 |
| Yagoda, A | 1 |
| Kelsen, DP | 1 |
| Gralla, RJ | 1 |
| Watson, RC | 1 |
| Greer, S | 1 |
| Schwade, J | 2 |
| Marion, HS | 1 |
| Redei, I | 1 |
| Green, F | 1 |
| Hoffman, JP | 1 |
| Weiner, LM | 3 |
| Scher, R | 1 |
| Fossum, B | 1 |
| Gedde-Dahl, T | 1 |
| Breivik, J | 1 |
| Eriksen, JA | 1 |
| Spurkland, A | 1 |
| Thorsby, E | 1 |
| Gaudernack, G | 1 |
| Ucar, A | 1 |
| Reddy, R | 1 |
| Livingstone, AS | 1 |
| Markoe, A | 1 |
| Richman, SP | 3 |
| Donofrio, K | 1 |
| Finkelstein, SD | 3 |
| Przygodzki, R | 1 |
| Pricolo, VE | 1 |
| Sayegh, R | 3 |
| Bakker, A | 2 |
| Swalsky, PA | 2 |
| Keller, G | 1 |
| Grem, JL | 2 |
| McAtee, N | 1 |
| Steinberg, SM | 1 |
| Hamilton, JM | 2 |
| Murphy, RF | 1 |
| Drake, J | 1 |
| Chisena, T | 1 |
| Balis, F | 1 |
| Cysyk, R | 1 |
| Arbuck, SG | 1 |
| Hudes, GR | 1 |
| Kitson, J | 1 |
| Walczak, J | 3 |
| Watts, P | 1 |
| Litwin, S | 2 |
| Swalsky, P | 1 |
| Christensen, S | 1 |
| Yang, JL | 1 |
| Fernandes, DJ | 1 |
| Wheeler, KT | 1 |
| Capizzi, RL | 1 |
| Wadler, S | 1 |
| Gleissner, B | 1 |
| Hilgenfeld, RU | 1 |
| Thiel, E | 1 |
| Haynes, H | 1 |
| Kaleya, R | 1 |
| Rozenblit, A | 1 |
| Kreuser, ED | 1 |
| Ragnhammar, P | 1 |
| Blomgren, H | 1 |
| Martino, RL | 1 |
| Fleming, TR | 2 |
| Morrell, LM | 2 |
| Köhne, CH | 2 |
| Wilke, H | 2 |
| Schöffski, P | 1 |
| Schmoll, HJ | 2 |
| Harstrick, A | 1 |
| Hiddemann, W | 1 |
| Preusser, P | 1 |
| Strumberg, D | 1 |
| Berns, T | 1 |
| Seeber, S | 1 |
| Burtscher, IM | 1 |
| Ståhlberg, F | 1 |
| Holtås, S | 1 |
| Yee, LK | 1 |
| Schuler, B | 1 |
| Chen, AP | 1 |
| Chabuk, C | 1 |
| Grollman, F | 1 |
| Grabenc, M | 1 |
| Takimoto, CH | 1 |
| Briscoe, WT | 1 |
| Griffin, AC | 1 |
| McBride, C | 1 |
| Bowen, JM | 1 |
| Tsuboi, KK | 1 |
| Kwong, LK | 1 |
| Kelsen, D | 1 |
| Martin, DS | 2 |
| Colofiore, J | 2 |
| Sawyer, R | 1 |
| Coit, D | 1 |
| Rosvold, E | 1 |
| Schilder, R | 1 |
| DiFino, SM | 1 |
| Flynn, PJ | 1 |
| Banerjee, TK | 1 |
| Heim, WJ | 1 |
| Engstrom, PF | 1 |
| Ozols, RF | 1 |
| Kemeny, N | 2 |
| Conti, JA | 1 |
| Seiter, K | 1 |
| Niedzwiecki, D | 1 |
| Botet, J | 1 |
| Martin, D | 1 |
| Costa, P | 1 |
| Wiseberg, J | 1 |
| McCulloch, W | 1 |
| Bach, A | 1 |
| Goodman, P | 1 |
| Paul, AR | 1 |
| Comis, RL | 1 |
| Schneider, A | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
| Floersheim, GL | 1 |
| Chiodetti, N | 1 |
| Bieri, A | 1 |
| Chiuten, DF | 2 |
| Valdivieso, M | 2 |
| Bedikian, A | 2 |
| Bodey, GP | 2 |
| Freireich, EJ | 2 |
| Miller, A | 1 |
| Loo, TL | 1 |
| Benvenuto, JA | 1 |
| Kadohama, N | 1 |
| Turkington, RW | 1 |
3 reviews available for aspartic acid and Adenocarcinoma
| Article | Year |
|---|---|
GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antigens, Surface; Aspartic Acid; Biomarkers, Tumor | 2019 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
9 trials available for aspartic acid and Adenocarcinoma
31 other studies available for aspartic acid and Adenocarcinoma
| Article | Year |
|---|---|
[Preparation, characterization and Calu-3 cellular uptake of three kinds of poly(b-benzyl-L-amino)block-poly(ethylene glycol) nanoparticles].
Topics: Adenocarcinoma; Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid; | 2013 |
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Asian People; Aspartic Acid; Female; Genetic Predispo | 2014 |
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Cyclin-Depen | 2010 |
N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aspartic Acid; Biopsy; Brain; Brain Neoplasms; Diagn | 2010 |
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Aspartic Acid; Cadherins; Down-Regulation; Gene Ex | 2011 |
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax.
Topics: Adenocarcinoma; Alitretinoin; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Aspartic Acid; bc | 2002 |
[Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing].
Topics: Adenocarcinoma; Asparagine; Aspartic Acid; Carcinoma, Squamous Cell; China; DNA; DNA Helicases; DNA | 2003 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.
Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Asparagine; Aspartic Acid; Carcinoma, Pancreatic Duct | 2007 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Phase II study of PALA and AMSA in advanced renal cell carcinoma.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; A | 1983 |
Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Topics: Adenocarcinoma; Aspartic Acid; Drug Evaluation; Humans; Kidney Neoplasms; Neoplasm Metastasis; Organ | 1982 |
Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Body Weight; Deoxycytidine; Idoxuridine; Mammary Neoplasms, | 1995 |
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Topics: Adenocarcinoma; Amino Acid Sequence; Aspartic Acid; CD4-Positive T-Lymphocytes; CD8 Antigens; Cells, | 1994 |
K-ras-2 topographic genotyping of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Alanine; Arginine; Aspartic Acid; Codon; Cysteine; DNA, Neoplasm; Exons; Forecasting | 1994 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.
Topics: Adenocarcinoma; Aspartic Acid; Biomarkers, Tumor; Codon; Colonic Neoplasms; DNA, Neoplasm; Exons; Fo | 1993 |
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra | 1993 |
PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartic Acid; Bromodeoxyuridine; Cell Division; DN | 1996 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 1997 |
Proton (1H) MR spectroscopy for routine diagnostic evaluation of brain lesions.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Diseases; Brain Neo | 1997 |
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 2001 |
The distribution and properties of aspartyl transfer RNA in human and animal tumors.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Carcinoma; Carcinoma, Ehrlich Tumor; Cells, Cultured; Cricet | 1975 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm | 1978 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Differential radioprotection of bone marrow and tumour cells by zinc aspartate.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Colonic Ne | 1988 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
Altered populations of acidic chromatin proteins in breast cancer cells.
Topics: Adenocarcinoma; Amino Acids; Animals; Aspartic Acid; Chromatin; Electrophoresis, Polyacrylamide Gel; | 1973 |